• Maze Therapeutics CEO Jason V. Coloma reported sales of 27,858 common shares on June 22-23.
• Shares sold at weighted average prices of $26 and $26.05.
• Holdings fell to 319,079 shares in the Coloma Family Trust.
• Holdings fell to 25,930 shares in The Coloma 2021 Irrevocable Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001676170-26-000012), on June 24, 2026, and is solely responsible for the information contained therein.